Philadelphia, March 26

Welcome to hubXchange’s Philadelphia Antibody Therapeutics Xchange 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

Doubletree by Hilton Philadelphia Airport,
4509 Island Avenue,
Philadelphia, PA, 19153, US


  • Different criteria for target selection depending on the type of biologic modality
  • Difficult targets: how to screen and prioritize candidates
  • Next generation antibodies addressing the road blocks for first generations
  • Challenges of using single domain antibodies as new modalities of multifunctional biologics
  • Considerations for CAR-T/ CAR-NK cell binder format designs during screening and selections
  • Novel technology to improve antibody access into solid tumors by using targeted enzymes
  • Bispecific Antibodies for T-cell Redirection
  • Novel delivery modes for biologics – beyond parenteral administration and beyond classical protein administration
  • Emerging antibody based immune targets and technologies

Full Xchange Agenda

Target Selection

Titles and Bullets
8:00 – 8:30
8:30 – 9:00

Opening Address & Keynote Presentation by WuXi Biologics

9:05 – 10:05
Different criteria for target selection depending on the type of biologic modality

Key issues in target selection:

  • therapeutic index,
  • resistance mechanisms,
  • OMICs platforms for target selection

Pavel Nikitin is an antibody engineer with 10+ years of industry experience in developing biologics for the treatment of cancer, inflammatory, and infectious diseases. Pavel heads Antibody Engineering group at Immunome, where he developed several therapeutics, including a novel immune modulator IMM-ONC-01 intended for treatment of solid tumors, and a neutralizing anti-viral cocktail IMM-BCP-01. Prior to joining Immunome, Pavel was a Senior Scientist at True North Therapeutics, a startup in SF Bay Area that developed a monoclonal antibody Sutimlimab (commercialized as Enjaymo by Sanofi). Pavel received his PhD in Molecular Genetics and Microbiology from Duke University.

Pavel Nikitin
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:45 – 11:15
1-2-1 Meetings/Networking Break
11:15 – 11:25
Morning refreshments
11:25 – 12:25
Sponsor-led Roundtable
12:25 – 13:25
Networking Lunch
13:25 – 13:55

Spotlight Presentation

14:00– 14:30
1-2-1 Meetings/Networking Break
14:35 – 15:05
1-2-1 Meetings/Networking Break
15:10 – 15:40
Poster Presentation
Lead Identification & Optimization topic: Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform
The Pioneer Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic discovery. The Pioneer Platform comprises a new antibody phage display library engineered to have optimal properties for the selection of therapeutic candidates, including the reduction of CDR-located posttranslational modification sites for improved developability. With 92% of the clones (VH and VL combined) encoding functional antibodies, the Pioneer Antibody Library encodes 2.25×1011 unique antibodies. Pioneer takes advantage of SpyDisplay, a novel selection system based on SpyTag technology. Herein, we demonstrate that the Pioneer Platform delivers diverse high-affinity antibody lead candidates. Using anti-TIGIT antibodies, we show that the performance of our lead candidates is comparable with antibodies undergoing clinical trials.
15:45 – 16:25
1-2-1 Meetings/Networking Break
17:30– 18:30
Drinks-Canape Reception


Antibody Therapeutics Xchange | Philadelphia 2024